The company’s shift involves a $12 million acquisition of commercial rights to Rebyota and Clenpiq from Ferring Pharmaceuticals, a move fully funded by the recent $18 million divestment of its Talicia interest. Rebyota, an FDA-approved fecal microbiota transplant for recurrent C. difficile infections, and Clenpiq, a low-volume bowel preparation, generated a combined $37.5 million in 2025 net sales. RedHill CEO Dror Ben-Asher stated that these assets provide the necessary control to scale operations and identify further complementary products for their existing U.S. GI infrastructure.
In section Releases
RedHill Biopharma Pivots to GI Commercialization After Portfolio Reset
RedHill Biopharma has completed a strategic overhaul, transitioning from a research-heavy entity to a commercial player focused on gastrointestinal health. By divesting its stake in Talicia and acquiring rights to Rebyota and Clenpiq, the company aims to leverage an established U.S. market presence to drive revenue growth throughout the second half of 2026.
Beyond commercial operations, RedHill is advancing its R&D pipeline, emphasizing oncology and infectious disease. Opaganib, the company’s lead candidate, has secured U.S. FDA rare pediatric disease designation for neuroblastoma, a milestone that could grant the company a Priority Review Voucher. Simultaneously, the firm continues to develop RHB-204 for Crohn’s disease and RHB-102 for GI-associated intolerances. Financially, the company reported a net loss of $6.1 million for the first half of 2026, though management maintains that the streamlined structure and new revenue-generating assets position the firm for improved operational efficiency in the coming quarters.
Comments (0)
No comments yet. Be the first!